Wockhardt shares jump 12% after US FDA accepts NDA for breakthrough antibiotic Zaynich

Zaynich is Wockhardt’s novel antibiotic candidate aimed at tackling resistant bacterial infections, an area where global innovation has been limited.

Leave a Reply

Your email address will not be published. Required fields are marked *